The Food and Drug Administration has delayed a promised review of safety data for the abortion drug mifepristone at Commissioner Marty Makary’s request to put it off until after the midterm elections,

Abortion medication access, like mifepristone, is unchanged under Trump, but FDA reviews, lawsuits and state enforcement are creating risks for drugmakers.

The ballot measure also includes a ban on gender affirming health care for minors. Judges reissued the summary statement that voters will see on November 2026 ballots to make clear rights were being repealed,